

**From:** Natalie Bemrose  
**Sent:** 05 October 2007 16:56  
**To:** Natalie Bemrose  
**Subject:** Technology Appraisal - Lung cancer (non-small cell) - bevacizumab

5 October 2007

**Sent by email**

Dear Consultee/Commentator

## **Health Technology Appraisal**

### **Lung cancer (non-small cell) – bevacizumab**

The Appraisal Committee are due to meet on 6 November 2007 to discuss the use of bevacizumab for NSCLC. As the Institute has not received a submission from the manufacturer of bevacizumab we are suspending the appraisal whilst we consider the next steps.

Please be assured we will update you on our progress and next steps as soon as possible.

If you have any questions or queries please contact the Project Manager for this appraisal, Natalie Bemrose (Natalie.Bemrose@nice.org.uk; 020 7067 5930)

Kind Regards,

Meindert Boysen

Meindert Boysen, *Pharmacist MSc HPPF*  
Associate Director Single Technology Appraisals  
National Institute for Health and Clinical Excellence (NICE)  
Peter House, Oxford Street, Manchester M1 5AN  
Phone: 0161 2093855  
Fax: 01612093889  
Mobile: 07879688065  
Website: [www.nice.org.uk](http://www.nice.org.uk)

**NICE is the independent organisation responsible for providing national guidance on the promotion of good health and the prevention and treatment of ill health.**

The information contained in this message or any of its attachments may be privileged and confidential and is intended for the exclusive use of the addressee(s). If you are not the addressee any disclosure, reproduction, distribution, other dissemination or use of this message is strictly prohibited. If you receive this message in error please return it to the sender and delete it from your system. Any personal data sent in reply will be processed by us in accordance with requirements of the Data Protection Act 1998 for the purposes of the Institute's work only. Further details are available on the NICE website [www.nice.org.uk](http://www.nice.org.uk) All messages sent by NICE are virus checked with the latest available product in order to minimise the risk of transmitting software viruses, but we advise you to carry out your own virus checks on any attachment to this message. We cannot accept liability for any loss or damage caused by software viruses.